Arca Biopharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABIO Nasdaq 2834 http://arcabio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arca Biopharma Inc

One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price - Jun 4th, 2019 5:09 am
ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure - May 13th, 2019 7:00 am
ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update - May 8th, 2019 2:30 pm
GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure - May 1st, 2019 6:30 am
ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial - Apr 23rd, 2019 6:30 am
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology - Mar 18th, 2019 6:30 am
Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine - Mar 6th, 2019 6:00 am
ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update - Feb 27th, 2019 2:15 pm
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug - Feb 20th, 2019 5:30 am
Zosano Appoints Linda Grais M.D., J.D. to Board of Directors - Jan 16th, 2019 6:30 am
ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling - Dec 26th, 2018 9:47 am
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial - Dec 20th, 2018 2:01 pm
ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update - Nov 14th, 2018 2:30 pm
GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions - Nov 12th, 2018 6:30 am
ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions - Nov 5th, 2018 6:30 am
Westminster biotech company receives second extension on delisting notice from Nasdaq - Oct 10th, 2018 2:16 pm
Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics - Oct 2nd, 2018 6:00 am
Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018 - Aug 3rd, 2018 7:45 am